Answers are grounded in this paper and cite their sources.
Ipilimumab has shown an overall survival benefit in 2 randomized phase III studies. A minority of patients achieve long-term disease control, highlighting the potential of this immunotherapeutic approach. In ongoing efforts, investigators are continuing to characterize these patients' unique clinical courses and correlate their responses with underlying mechanisms of antitumor immunity.
No takes yet. Share an insight, caveat, or question.
Postow et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: